Literature DB >> 35213009

Design of Bifunctional Antisense Oligonucleotides for Exon Inclusion.

Haiyan Zhou1,2.   

Abstract

Bifunctional antisense oligonucleotide (AON) is a specially designed AON to regulate pre-messenger RNA (pre-mRNA) splicing of a target gene. It is composed of two domains. The antisense domain contains sequences complementary to the target gene. The tail domain includes RNA sequences that recruit RNA binding proteins which may act positively or negatively in pre-mRNA splicing. This approach can be designed as targeted oligonucleotide enhancers of splicing, named TOES, for exon inclusion; or as targeted oligonucleotide silencers of splicing, named TOSS, for exon skipping. Here, we provide detailed methods for the design of TOES for exon inclusion, using SMN2 exon 7 splicing as an example. A number of annealing sites and the tail sequences previously published are listed. We also present methodology of assessing the effects of TOES on exon inclusion in fibroblasts cultured from a SMA patient. The effects of TOES on SMN2 exon 7 splicing were validated at RNA level by PCR and quantitative real-time PCR, and at protein level by western blotting.
© 2022. The Author(s).

Entities:  

Keywords:  Antisense oligonucleotide; Bifunctional antisense; Exon inclusion; Exon skipping; Pre-mRNA splicing; Splice switching; TOES

Mesh:

Substances:

Year:  2022        PMID: 35213009     DOI: 10.1007/978-1-0716-2010-6_3

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.

Authors:  Eugenio Mercuri; Basil T Darras; Claudia A Chiriboga; John W Day; Craig Campbell; Anne M Connolly; Susan T Iannaccone; Janbernd Kirschner; Nancy L Kuntz; Kayoko Saito; Perry B Shieh; Már Tulinius; Elena S Mazzone; Jacqueline Montes; Kathie M Bishop; Qingqing Yang; Richard Foster; Sarah Gheuens; C Frank Bennett; Wildon Farwell; Eugene Schneider; Darryl C De Vivo; Richard S Finkel
Journal:  N Engl J Med       Date:  2018-02-15       Impact factor: 91.245

2.  Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Authors:  Richard S Finkel; Eugenio Mercuri; Basil T Darras; Anne M Connolly; Nancy L Kuntz; Janbernd Kirschner; Claudia A Chiriboga; Kayoko Saito; Laurent Servais; Eduardo Tizzano; Haluk Topaloglu; Már Tulinius; Jacqueline Montes; Allan M Glanzman; Kathie Bishop; Z John Zhong; Sarah Gheuens; C Frank Bennett; Eugene Schneider; Wildon Farwell; Darryl C De Vivo
Journal:  N Engl J Med       Date:  2017-11-02       Impact factor: 91.245

Review 3.  Nusinersen: First Global Approval.

Authors:  Sheridan M Hoy
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

4.  Splicing of a critical exon of human Survival Motor Neuron is regulated by a unique silencer element located in the last intron.

Authors:  Nirmal K Singh; Natalia N Singh; Elliot J Androphy; Ravindra N Singh
Journal:  Mol Cell Biol       Date:  2006-02       Impact factor: 4.272

5.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

6.  Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides.

Authors:  Z Dominski; R Kole
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

7.  Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.

Authors:  Yimin Hua; Kentaro Sahashi; Frank Rigo; Gene Hung; Guy Horev; C Frank Bennett; Adrian R Krainer
Journal:  Nature       Date:  2011-10-05       Impact factor: 49.962

8.  Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy.

Authors:  Diane E Frank; Frederick J Schnell; Cody Akana; Saleh H El-Husayni; Cody A Desjardins; Jennifer Morgan; Jay S Charleston; Valentina Sardone; Joana Domingos; George Dickson; Volker Straub; Michela Guglieri; Eugenio Mercuri; Laurent Servais; Francesco Muntoni
Journal:  Neurology       Date:  2020-03-05       Impact factor: 9.910

9.  Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Authors:  Maria Kinali; Virginia Arechavala-Gomeza; Lucy Feng; Sebahattin Cirak; David Hunt; Carl Adkin; Michela Guglieri; Emma Ashton; Stephen Abbs; Petros Nihoyannopoulos; Maria Elena Garralda; Mary Rutherford; Caroline McCulley; Linda Popplewell; Ian R Graham; George Dickson; Matthew J A Wood; Dominic J Wells; Steve D Wilton; Ryszard Kole; Volker Straub; Kate Bushby; Caroline Sewry; Jennifer E Morgan; Francesco Muntoni
Journal:  Lancet Neurol       Date:  2009-08-25       Impact factor: 44.182

10.  A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.

Authors:  Haiyan Zhou; Narinder Janghra; Chalermchai Mitrpant; Rachel L Dickinson; Karen Anthony; Loren Price; Ian C Eperon; Stephen D Wilton; Jennifer Morgan; Francesco Muntoni
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.